Source comparison
Stroke Recovery Peptides 2026 Update: Evidence vs Speculation Comparison
Cerebrolysin TrkB receptor agonism (BDNF mimetic) Phase III RCTs (n>1,500), Cochrane review 2025 30–50ml IV daily × 10–21 days 0–72 hours post-stroke Strongest evidence for functional recovery when started within 24 hours Dihexa HGF/c-Met potentiation (synapto
This comparison does not assign a generated winner or score.
- Cerebrolysin
- TrkB receptor agonism (BDNF mimetic)
- Phase III RCTs (n>1,500), Cochrane review 2025
- 30–50ml IV daily × 10–21 days
- 0–72 hours post-stroke
- Strongest evidence for functional recovery when started within 24 hours
- Dihexa
- HGF/c-Met potentiation (synaptogenesis)
- Phase I safety data only; extensive preclinical models
- 5–10mg oral daily × 28 days
- 0–7 days (preclinical)
- Promising mechanism but limited human stroke data; safety profile established
- P21
- STAT3 activation (neuronal survival)
- Phase II ongoing (2026)
- 1mg/kg subcutaneous × variable
- 0–6 hours (preclinical)
- Strong preclinical neuroprotection; human efficacy data pending Q3 2026
- Thymalin
- Immune modulation (T-reg expansion)
- Small pilot (n=42); cognitive endpoints
- 10mg IM 3× weekly × 6 weeks
- 0–14 days
- Modest cognitive benefit; indirect mechanism; weak evidence base
- Semax
- ACTH fragment (neuroprotection)
- Small Russian trials (n<100); no Western replication
- Intranasal 0.1% solution
- 0–24 hours
- Historical use but insufficient modern trial data